Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Unimark Remedies
Mumbai, Maharashtra, India
- Ownership
- Private
- Employees
- ~570
- Development stage
- Other
01
Overview
Unimark Remedies manufactures a broad range of generic pharmaceutical APIs and finished formulations, with multiple internationally approved production facilities. Their drugs target respiratory, cardiovascular, anti-infective, and CNS indications, among others. They also focus on diagnostics, devices, and cosmeceuticals. Recent acquisition by Shamrock Pharmagroup in 2024, and facilities compliant with USFDA, EUGMP, and other major regulatory agencies.
- Therapeutic areas
- Infectious DiseasesPulmonologyCardiovascularOtherNeurology
- Modalities
- Small moleculeBiologic
- Industry
- Contract Manufacturing Organization
Beyond the preview
Go deeper on Unimark Remedies.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unimark Remedies.